Acquisition of portfolio company 89Bio by Roche

Summary by AI BETAClose X

International Biotechnology Trust PLC (IBT) noted Roche's acquisition of 89Bio for up to $3.5 billion, representing an approximate 80% premium over 89Bio's closing share price on September 17, 2025. 89Bio represents 0.5% of IBT's net asset value as of the same date. IBT's NAV total return performance as of August 30, 2025, was +23.43% over five years, +20.98% over three years, and +1.76% over one year, outperforming the Nasdaq Biotechnology Index which showed +13.16%, +6.94%, and -6.00% respectively over the same periods. The updated valuation from the acquisition will be included in IBT's NAV as at close of business on September 18, 2025.

Disclaimer*

UK 100

Latest directors dealings